TPG Affiliates Affirm Support for Rallybio's Merger with Candid Therapeutics
Summary
A major institutional investor, TPG, has formally committed its 7.2% stake to support Rallybio Corp's proposed reverse merger with Candid Therapeutics.
Key Events
-
Major Shareholder Support
TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, collectively hold 378,551 shares, representing 7.2% of Rallybio's common stock.
-
Merger Support Agreement
TPG's Rise Fund Rascal has entered into a Support Agreement, committing to vote all its shares in favor of the definitive merger agreement with Candid Therapeutics, Inc., which was announced on March 2, 2026.
-
Strategic Alignment
The agreement also stipulates that TPG will vote against any proposals opposing the merger and will not solicit alternative acquisition proposals, reinforcing the strategic direction.
Analysis
This Schedule 13D/A confirms that TPG GP A, LLC and its principals, holding a significant 7.2% stake in Rallybio Corp, have entered into a Support Agreement to vote in favor of the recently announced reverse merger with Candid Therapeutics, Inc. This public commitment from a major institutional investor strengthens the likelihood of the merger's successful completion, providing crucial backing for the company's strategic transformation, following the definitive merger agreement announced on March 2, 2026.
At the time of this filing, RLYB was trading at $10.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.5M. The 52-week trading range was $1.76 to $11.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.